INTRODUCTION {#sec1}
============

Human papillomavirus (HPV) DNA testing has proven to be an effective primary screening approach for the secondary prevention of cervical cancer in developing countries ([@B1], [@B2]). The assays for detecting HPV offer important advantages, including greater reliability and easier implementation, because these molecular tests do not require specialized medical training to obtain samples ([@B3], [@B4]). Currently, however, most HPV detection assays rely on liquid-based cytology (LBC) medium. In low-resource settings, where the use of Pap testing is limited, LBC medium adds cost, is difficult to transport, and represents a waste disposal challenge. Therefore, safer and more convenient methods of specimen collection and transport that do not compromise test performance are needed. In the present study, we aimed to investigate the stability of cervical specimens collected by swab and stored dry at ambient room temperature, using HPV DNA testing.

RESULTS {#sec2}
=======

Specimens were collected from 743 women; 695 women were included for data analysis, however, because there were 48 ineligible cases. Two LBC samples and four swab samples were tested but yielded invalid results. There were 30 cases with no biopsy results among 689 women with valid cobas HPV results. A total of 689 cases were used for agreement analysis, and 659 cases were used to analyze the accuracy of swab and LBC samples for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and CIN grade 3 or worse (CIN3+) with the cobas HPV test. Characteristics of the 695 eligible women are presented in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of 695 eligible women

  Characteristic                                     No. (%)
  -------------------------------------------------- -------------
  Age                                                
      \<35 yr                                        220 (31.7)
      35--44 yr                                      262 (37.7)
      ≥45 yr                                         213 (30.7)
  Reason for colposcopy                              
      Abnormal cytological or HPV-positive results   654 (94.1)
      Other reasons                                  41 (5.9)
  Colposcopy result                                  
      Normal                                         30 (4.3)
      Abnormal                                       658 (94.7)
      Missing                                        7 (1.0)
  Biopsy result                                      
      Negative[^*a*^](#T1F1){ref-type="table-fn"}    312 (44.9)
      CIN1                                           108 (15.5)
      CIN2                                           47 (6.8)
      CIN3                                           150 (21.6)
      Invasive cervical cancer                       48 (6.9)
  Storage time                                       
      2 days                                         168 (24.2)
      7 days                                         178 (25.6)
      14 days                                        175 (25.2)
      28 days                                        174 (25.0)
  Total                                              695 (100.0)

Normal or non-CIN/cervical cancer.

The prevalence of high-risk HPVs (HR-HPVs) overall, 12 pooled HR-HPVs, HPV16, and HPV18, as detected by cobas HPV testing with LBC and swab samples, is shown in [Table 2](#T2){ref-type="table"}. There were no significant differences in the distributions of HR-HPVs overall, 12 pooled HR-HPVs, HPV16, and HPV18 between LBC and swab samples, with *P* values of 0.61, 0.33, 0.73, and 0.91, respectively. There was also no significant difference in the distribution of invalid cases between LBC and swab samples (*P* = 0.41).

###### 

Prevalence for HR-HPVs overall, 12 pooled HR-HPVs, HPV16, and HPV18 by cobas 4800 HPV testing with LBC and swab samples

  HPV type            Prevalence (% \[no. positive/total no. tested\])   *P*              
  ------------------- -------------------------------------------------- ---------------- ------
  HR-HPVs overall     61.9 (429/693)                                     63.2 (437/691)   0.61
  12 pooled HR-HPVs   42.9 (297/693)                                     45.4 (314/691)   0.33
  HPV16               22.4 (155/693)                                     23.2 (160/691)   0.73
  HPV18               4.9 (34/693)                                       4.8 (33/691)     0.91
  Invalid result      0.3 (2/695)                                        0.6 (4/695)      0.41

The kappa values for agreement between findings for LBC and swab samples detected by cobas HPV testing, stratified according to storage time, are presented in [Table 3](#T3){ref-type="table"}. The kappa values for HR-HPVs overall, 12 pooled HR-HPVs, HPV16, and HPV18 in LBC and swab samples were 0.87 (95% confidence interval \[CI\], 0.83 to 0.91), 0.86 (95% CI, 0.82 to 0.90), 0.94 (95% CI, 0.91 to 0.97), and 0.94 (95% CI, 0.87 to 1.00), respectively. The numbers of HR-HPVs overall, 12 pooled HR-HPVs, HVP16, and HPV18 detected in LBC and swab samples by cobas HPV testing agreed well at storage times of 2, 7, and 28 days; however, the storage time of 14 days showed a slightly lower kappa value (0.76 \[95% CI, 0.66 to 0.86\]) for HR-HPVs overall, compared to that at 7 days (0.93 \[95% CI, 0.87 to 0.98\]). The sensitivity and specificity for detecting CIN2+ and CIN3+ by cobas 4800 HPV testing using LBC and swab samples are shown in [Table 4](#T4){ref-type="table"}. There was no significant difference in the sensitivity and specificity for detecting CIN2+ and CIN3+ with these two sample types using the cobas HPV test, regardless of storage time.

###### 

Agreement between LBC and swab samples tested by the cobas 4800 HPV test

  Storage time and HPV type         No.   Agreement rate (% \[95% CI\])   Kappa (95% CI)                               
  --------------------------------- ----- ------------------------------- ---------------- ----- --------------------- -------------------
  Total (*n* = 689)                                                                                                    
      HR-HPVs overall               235   26                              17               411   93.8 (91.7--95.3)     0.87 (0.83--0.91)
      12 pooled HR-HPVs             360   32                              15               282   93.2 (91.1--94.8)     0.86 (0.82--0.90)
      HPV16                         524   10                              5                150   97.8 (96.4--98.7)     0.94 (0.91--0.97)
      HPV18                         654   2                               2                31    99.4 (98.5--99.8)     0.94 (0.87--1.00)
  Storage for 2 days (*n* = 168)                                                                                       
      HR-HPVs overall               65    6                               3                94    94.6 (90.1--97.2)     0.89 (0.82--0.96)
      12 pooled HR-HPVs             89    8                               5                66    92.3 (87.2--95.4)     0.84 (0.76--0.92)
      HPV16                         135   1                               0                32    99.4 (96.7--99.9)     0.98 (0.94--1.00)
      HPV18                         163   0                               0                5     100.0 (97.8--100.0)   1.00 (1.00--1.00)
  Storage for 7 days (*n* = 176)                                                                                       
      HR-HPVs overall               59    4                               2                111   96.6 (92.8--98.4)     0.93 (0.87--0.98)
      12 pooled HR-HPVs             92    7                               2                75    94.9 (90.6--97.3)     0.90 (0.83--0.96)
      HPV16                         132   3                               1                40    97.7 (94.3--99.1)     0.94 (0.88--1.00)
      HPV18                         165   0                               1                10    99.4 (96.9--99.9)     0.95 (0.85--1.00)
  Storage for 14 days (*n* = 174)                                                                                      
      HR-HPVs overall               61    12                              8                93    88.5 (82.9--92.4)     0.76 (0.66--0.86)
      12 pooled HR-HPVs             94    11                              4                65    91.4 (86.3--94.7)     0.82 (0.74--0.91)
      HPV16                         131   2                               4                37    96.6 (92.7--98.4)     0.90 (0.83--0.98)
      HPV18                         167   2                               1                4     98.3 (95.1--99.4)     0.72 (0.41--1.00)
  Storage for 28 days (*n* = 171)                                                                                      
      HR-HPVs overall               50    4                               4                113   95.3 (91.0--97.6)     0.89 (0.82--0.96)
      12 pooled HR-HPVs             85    6                               4                76    94.2 (89.6--96.8)     0.88 (0.81--0.95)
      HPV16                         126   4                               0                41    97.7 (94.1--99.1)     0.94 (0.88--1.00)
      HPV18                         159   0                               0                12    100.0 (97.8--100.0)   1.00 (1.00--1.00)

###### 

Sensitivity and specificity for detecting CIN2+ and CIN3+ using cobas 4800 HPV testing with LBC and swab samples

  Storage time and sample type      CIN2+               CIN3+                                   
  --------------------------------- ------------------- ------------------- ------------------- -------------------
  Total (*n* = 659)                                                                             
      LBC                           91.4 (87.2--94.3)   53.7 (48.9--58.5)   92.9 (88.4--95.7)   49.8 (45.2--54.3)
      Swab                          93.4 (89.6--95.9)   52.8 (48.0--57.5)   93.9 (89.7--96.5)   48.3 (43.7--52.8)
  Storage for 2 days (*n* = 161)                                                                
      LBC                           89.5 (78.9--95.1)   56.7 (47.1--65.9)   89.6 (77.8--95.5)   53.1 (44.0--62.0)
      Swab                          89.5 (78.9--95.1)   55.8 (46.2--64.9)   89.6 (77.8--95.5)   52.2 (43.1--61.2)
  Storage for 7 days (*n* = 170)                                                                
      LBC                           96.7 (88.8--99.1)   53.2 (43.9--62.3)   98.0 (89.5--99.7)   49.2 (40.4--58.0)
      Swab                          98.4 (91.3--99.7)   51.4 (42.1--60.6)   98.0 (89.5--99.7)   46.7 (38.0--55.6)
  Storage for 14 days (*n* = 164)                                                               
      LBC                           86.7 (75.8--93.1)   57.7 (48.1--66.8)   91.1 (79.3--96.5)   53.8 (44.9--62.5)
      Swab                          93.3 (84.1--97.4)   56.7 (47.1--65.9)   95.6 (85.2--98.8)   51.3 (42.4--60.1)
  Storage for 28 days (*n* = 164)                                                               
      LBC                           92.4 (83.5--96.7)   46.9 (37.4--56.8)   92.6 (82.5--97.1)   42.7 (33.9--52.1)
      Swab                          92.4 (83.5--96.7)   46.9 (37.4--56.8)   92.6 (82.5--97.1)   42.7 (33.9--52.1)

DISCUSSION {#sec3}
==========

The performance in detecting HR-HPVs overall, 12 pooled HR-HPVs, HPV16, and HPV18 with dry-stored swab samples, which were stored at uncontrolled ambient temperatures for 1 month, was equal to that with LBC specimens using the cobas HPV test. The accuracy of detecting CIN2+ or CIN3+ with dry-stored swab samples with 1 month of storage was comparable to that with LBC specimens. Our study also showed a common limitation of the HPV test, i.e., low specificity for detecting cervical precancerous lesions, with both LBC and swab samples. In this respect, genotyping of HPV16 and HPV18 with the cobas HPV test can compensate for the loss of specificity ([@B5]). Of note, although the kappa value for HR-HPVs overall with the two sample types at a storage time of 14 days was slightly lower than that at 7 days, with marginal significance, no significant difference was seen in terms of accuracy in detecting CIN2+ and CIN3+ using the cobas HPV test with LBC and swab samples. The results demonstrated excellent agreement between LBC and swab samples for detection of HR-HPVs overall, 12 pooled HR-HPVs, HPV16, and HPV18 with the cobas HPV test.

Several studies demonstrated that the testing performance of LBC samples did not decline over time ([@B6][@B7][@B8]). In the current study, commonly used LBC samples were selected as a reference to evaluate the stability of swab samples. A series of studies compared the performance of dry and wet cervicovaginal samples in HPV assays, but the stability of the two sample types was not evaluated ([@B9][@B10][@B15]). Our study is the first, to the best of our knowledge, to demonstrate the stability of dry and wet cervical samples for HPV DNA testing, but we did not evaluate the performance of vaginal or self-collected samples in cobas HPV testing by means of the current dry-collected and dry-stored approach. Studies indicate that the strategy of self-collecting samples for HPV testing is effective in improving cervical screening coverage ([@B16], [@B17]). PCR-based HPV DNA tests have shown similar sensitivities with self-collected samples and clinician-collected samples ([@B18]). Whether cobas HPV testing can facilitate the approach of dry and self-collected sampling in cervical cancer screening programs should be further investigated.

The limitations of the current study are as follows. First, the accuracy of dry sample collection for detecting HPV and cervical precancerous lesions, compared to the liquid-based sampling strategy, was evaluated among patients at a colposcopic clinic rather than in the general female population. Second, the processing time for dry-collected and stored swab samples exceeded that of routine methods. The feasibility of shorter periods of vortex-mixing for preparation of dry swab samples should be further tested. In conclusion, swab-collected samples can last up to 1 month in dry storage without loss of test performance, compared to traditional LBC samples, which may offer a simple inexpensive approach of sampling in cervical cancer screening programs in low-resource settings.

MATERIALS AND METHODS {#sec4}
=====================

Study population. {#sec4-1}
-----------------

A parallel comparative experimental study was conducted in the Cancer Hospital, Chinese Academy of Medical Sciences, collaborating with the West China Second University Hospital, Sichuan University. Patients with abnormal cytological findings and/or HPV-positive results were recruited at the time of the colposcopy examination. All women supplied written informed consent. We excluded participants who were pregnant or had a history of total hysterectomy.

Sample collection and storage. {#sec4-2}
------------------------------

Two cervical specimens from each woman were randomly collected by the physician prior to colposcopic evaluation. One sample was collected using a CytoBrush and placed into PreservCyt medium (Hologic, Crawley, United Kingdom) (LBC sample), and one sample was collected using a polyethylene fiber swab and placed into a Sarstedt 15-ml tube (swab sample). The swab and Sarstedt 15-ml tube were provided by Roche Molecular Systems (Branchburg, NJ). The specimens were randomly assigned to be stored at uncontrolled ambient temperatures (0 to 30°C) for fixed times of 2, 7, 14, or 28 days. After storage at room temperature according to the protocol, the specimens were stored at −20°C until HPV DNA testing was performed. The specimens were stored at −20°C from 3 months to 6 months before HPV DNA testing was performed.

Colposcopy and biopsy. {#sec4-3}
----------------------

Women classified as having a cervical abnormality by digital colposcopy underwent a biopsy. All pathology slides were read by the pathologists at the West China Second University Hospital, Sichuan University. Ten percent of the CIN1 and CIN3 cases (selected randomly) and all CIN2 cases were subjected to review by the pathologists at the Cancer Hospital, Chinese Academy of Medical Sciences, for quality control.

HPV DNA testing. {#sec4-4}
----------------

The cobas HPV testing was performed in the laboratory of the West China Second University Hospital, Sichuan University, according to the manufacturer\'s instructions, except as noted below. The cobas HPV test provides specific genotyping results for HPV16 and HPV18 along with results for 12 pooled oncogenic types, i.e., HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66, and HPV68. Specimen preparation for the cobas HPV test was accomplished using the cobas x 480 instrument, which simultaneously extracts, purifies, and prepares target HPV DNA and β-globin DNA for PCR amplification and detection. The processing of β-globin DNA functions as a control to differentiate HPV-negative specimens from samples that fail to exhibit positivity due to a lack of cells or the presence of PCR inhibitors in the specimens being tested. For the dry swab specimens, we added 1.2 ml PreservCyt medium into the tube with the dry swab specimen and then vortex-mixed the sample for 15 min. After vortex-mixing, the swab was removed from the tube. The tube with the sample eluted from the dry swab was then placed in the cobas 4800 instrument for DNA extraction and HPV detection.

Statistical analysis. {#sec4-5}
---------------------

From PASS software, a sample size of 168 pairs achieved 80% power to detect an odds ratio of 3.00 using a two-sided McNemar test, with a significance level of 0.05. We evaluated the agreement of results for HR-HPVs overall, HPV16, HPV18, and 12 pooled HR-HPV strains detected by cobas HPV testing with swab and LBC specimens for each storage time (2, 7, 14, and 28 days), by means of McNemar tests. We calculated the sensitivity and specificity for detecting CIN2+ and CIN3+ using cobas HPV testing with LBC and swab samples. All *P* values of \<0.05 (two-sided) were considered statistically significant. The statistical analysis was conducted using SAS version 9.2 (SAS Institute, Cary, NC).
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